DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that they held an end of Phase 2 meeting with U.S. Food and Drug Administration (FDA) to review the conduct of a successfully completed multicenter Phase 2 study of Lymphoseek®. In addition, Neoprobe and FDA reviewed proposed protocols for Phase 3 clinical studies of Lymphoseek. At the conclusion of the discussion, Neoprobe and FDA were in concurrence regarding the design of the Phase 3 studies.
